




Name	Pyoeng Gyun Choe	
Current Position	Clinical Professor, Seoul National University Hospital	
Country	Republic of Korea	
Major Field	Infectious Diseases	

Educational Background

1996 – 1998 Premedical Course, Seoul National University College of Natural Science
 1998 – 2002 M.D., Seoul National University College of Medicine
 2006 – 2011 M.S. in Medicine, Seoul National University College of Medicine
 2011 – 2017 Ph.D. in Medicine, Seoul National University College of Medicine
 2018 – 2019 M.P.H., Johns Hopkins Bloomberg School of Public Health
 (Concentration on Epidemiological and Biostatistical Methods for Public Health and Clinical Research)

Professional Experience

Mar 2011 – Present:
 Clinical Assistant Professor/Associate Professor/Professor,
 Division of Infectious Diseases
 Department of Internal Medicine, Seoul National University Hospital

Sep 2012 – June 2018, Sep 2020 – Present:
 Chief of Biocontainment Unit
 Seoul National University Hospital

Other Experience and Professional Memberships

May 2007 – Apr 2010: Epidemic Intelligence Service Officer
 Korea Centers for Disease Control

Sep 2016 – Present: Committee Member
 Korea National Healthcare-associated Infection Surveillance System



Main Scientific Publications

1. Chang E, Im D, Lee HY, Lee M, Lee CM, Kang CK, Park WB, Kim NJ, **CHOE PG**, Oh M. Impact of discontinuing isolation in a private room for patients infected or colonized with vancomycin-resistant enterococci (VRE) on the incidence of healthcare-associated VRE bacteraemia in a hospital with a predominantly shared-room setting. *J Hosp Infect.* 2023;132:1-7. (corresponding author)
2. **CHOE PG**, Hong J, Park J, Chang E, Kang CK, Kim NJ, Lee CH, Park WB, Oh MD. Persistent Antibody Responses up to 18 Months after Mild SARS-CoV-2 Infection. *J Infect Dis.* 2022;226(7):1224-30.
3. Jung J, **CHOE PG**, Choi S, Kim E, Lee HY, Kang CK, Lee J, Park WB, Lee S, Kim NJ, Choi EH, Oh M. Reduction in the acquisition rate of carbapenem-resistant *Acinetobacter baumannii* (CRAB) after room privatization in an intensive care unit. *J Hosp Infect.* 2022;121:14-21. (corresponding author)
4. **CHOE PG**, Kang CK, Kim KH, Yi J, Kim ES, Park SW, Kim NJ, Park WB, Oh MD. Persistence of Neutralizing Antibody Response up to One Year after Asymptomatic or Symptomatic SARS-CoV-2 infection. *J Infect Dis.* 2021;224(6):1097-9
5. **CHOE PG**, Kim KH, Kang CK, Suh HJ, Kang E, Lee SY, Kim NJ, Yi J, Park WB, Oh MD. Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection. *Emerg Infect Dis.* 2021;27(3):928-31.
6. **CHOE PG**, Kang CK, Suh HJ, Jung J, Song KH, Bang JH, Kim ES, Kim HB, Park SW, Kim NJ, Park WB, Oh MD. Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection. *Emerg Infect Dis.* 2021;27(1):327-9.
7. **CHOE PG**, Lim J, Kim EJ, Kim JH, Shin MJ, Kim SR, Choi JY, Choi YH, Lee KW, Koo H, Lee H, Song KH, Kim ES, Kim NJ, Oh MD, Kim HB. Impact of national policy on hand hygiene promotion activities in hospitals in Korea. *Antimicrob Resist Infect Control.* 2020;9(1):157.
8. **CHOE PG**, Park WB, Choi SJ, Kang CK, Koh Y, Kim NJ, Oh MD. Prolonged (6-Month) Shedding of Middle East Respiratory Syndrome Coronavirus RNA in the Sputum of a Lymphoma Patient. *Open Forum Infect Dis.* 2020;7(8):ofaa292.
9. **CHOE PG**, Kang CK, Suh HJ, Jung J, Kang E, Lee SY, Song KH, Kim HB, Kim NJ, Park WB, Kim ES, Oh MD. Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients. *Emerg Infect Dis.* 2020;26(10):2484-7.